VRCA
Verrica Pharmaceuticals Inc. Common Stock
stockNASDAQ
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.60 | 2026-09-28 | -4.78% | -6.254 |
| 1M | 5.30 | 2026-09-04 | -17.36% | 0.647 |
| 3M | 6.13 | 2026-07-06 | -28.55% | 0.877 |
| 6M | 5.98 | 2026-04-06 | -26.76% | 1.372 |
| 1Y | 4.67 | 2025-10-03 | -6.21% | 2.019 |
| 2Y | 13.10 | 2024-10-04 | -66.56% | — |
| 5Y | 121.40 | 2021-10-04 | -96.39% | 0.985 |
Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA) stock price today is $4.38, and today's volume is 44,715. VRCA is down 2.990% today. The 30 day average volume is 78,457. VRCA market cap is $75.24M with 17.18M shares outstanding.